More Treatment, Worse Outcomes: The $450 Billion Industry That Grows When You Don't Get Better
Published free for all readers. Share with attribution.
US mental health spending increased by 241% between 2000 and 2021. During the same period, suicide rates rose by approximately 30%. Depression and anxiety symptoms are now reported by nearly a third of the adult US population.
More money. More therapists. More prescriptions. More awareness campaigns. And by every measurable population-level outcome: worse results.
This is not a funding gap. It is not a failure of effort. In 2022, researchers gave this pattern a name: the treatment-prevalence paradox. Their finding was precise and damning. Treatments for depression have improved. Their availability has expanded dramatically. The number of people receiving treatment increased fourfold between 1987 and 2007. Population-level prevalence of depression has not decreased. It may have increased.
The global mental health market is now valued at approximately USD $451 billion. It grows consistently, year on year, as outcomes stagnate or worsen.
This is the subject of our new research analysis: CN-002, published in the LUMINA Research library.
The analysis examines what seven independent explanations for the treatment-prevalence paradox actually reveal, what 30 years of Australian mental health reform data show, and what three LUMINA Framework modules teach about why a system can grow indefinitely while failing to address the problem it claims to solve.
The answer has nothing to do with funding. And the industry has a structural incentive to make sure you never hear it.